

**REMARKS**

This submission is in response to the Official Action dated April 9, 2003. Claims 1-21 are pending. Consideration of the above identified application, in view of the following remarks, is respectfully requested. No new matter has been added by way of this amendment.

**Restriction Requirement**

In the Office Action, the Examiner has required election of one of the following groups of claims:

I. Claims 1, 2, 4-8 are drawn to a method of treating adenocarcinoma classified in Class 424, subclass 93.1.

II. Claims 1, 3, 4-8 are drawn to a method of treating leukemia classified in Class 424, subclass 93.1.

III. Claim 9 drawn to a method of eliciting T lymphocytes to infiltrate an adenocarcinoma tumor classified in Class 424, subclass 93.1.

IV. Claim 9 drawn to a method of eliciting T lymphocytes to infiltrate a leukemia tumor classified in Class 424, subclass 93.1.

V. Claim 10 drawn to a method of eliciting an inflammatory immune response to an adenocarcinoma tumor classified in Class 424, subclass 93.1.

VI. Claim 10 drawn to a method of eliciting an inflammatory immune response to a leukemia tumor classified in Class 424, subclass 93.1.

VII. Claim 11 drawn to a method of eliciting delayed type hypersensitivity response to an adenocarcinoma tumor classified in Class 424, subclass 93.1.

VIII. Claim 11 drawn to a method of eliciting delayed type hypersensitivity response to a leukemia tumor classified in Class 424, subclass 93.1.

IX. Claims 12, 13, 15-21 drawn to a composition for treating ovarian carcinoma tumor classified in Class 424, subclass 93.1.

X. Claims 12, 13, 15-21 drawn to a composition for treating colon carcinoma tumor classified in Class 424, subclass 93.1.

XI. Claims 12, 14-21 drawn to a composition for treating leukemia tumor classified in Class 424, subclass 93.1.

In response, Group I, corresponding to claims 1, 2 and 4-8, is hereby elected, without traverse.

Early and favorable consideration of this response and the claims is earnestly solicited. If there are any other issues remaining which the Examiner believes could be resolved through either a Supplemental Response or an Examiner's Amendment, the Examiner is respectfully requested to contact the undersigned at the telephone number indicated below.

Respectfully submitted,



Anna Löqvist, Ph.D.  
Limited Recognition Under 37 C.F.R.  
10.9(b) (see attached)  
Representative of Applicants

DARBY & DARBY, P.C.  
Post Office Box 5257  
New York, NY 10150-5257  
Phone (212) 527-7700